GlobeNewswire Inc.··NaAdaptin Bio Gains OTCQB Listing as Glioblastoma Drug Enters Clinical Trials
Adaptin Bio ($APTN) approved for OTCQB quotation. Lead program APTN-101, a brain bispecific T cell engager for glioblastoma, receives FDA clearance for Phase 1 trials.
APTNPhase 1 clinical trialglioblastoma